Summary
This 8-K filing from Edwards Lifesciences Corporation (EW), dated July 22, 2008, primarily announces the company's financial results for the second quarter of 2008. The report includes a press release detailing these results, which is attached as Exhibit 99.1. Investors should note that while the press release contains significant information, only the first two paragraphs and pages 6-10 are considered "filed" with the SEC, meaning they are subject to liability under the Exchange Act. The rest of the press release is furnished but not filed. The key takeaway for investors is the announcement of Q2 2008 financial performance. While the specific financial figures are not detailed within the 8-K itself but rather in the referenced press release, this filing serves as the official notification of these results to the market. Investors and analysts will need to refer to the attached press release for the detailed earnings, revenue, and any other financial metrics disclosed for the period.
Key Highlights
- 1Edwards Lifesciences announced its second quarter 2008 financial results on July 22, 2008.
- 2The detailed financial results are provided in a press release, attached as Exhibit 99.1 to the 8-K filing.
- 3The filing serves as official notification to the market of the company's Q2 2008 performance.
- 4Only specific sections of the press release (first two paragraphs and pages 6-10) are deemed 'filed' under the Exchange Act.
- 5The Chief Financial Officer and Treasurer, Thomas M. Abate, signed the report, indicating CFO-level oversight of the financial disclosure.